StockNews.com Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

Investment analysts at StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Down 3.3 %

Tenax Therapeutics stock opened at $3.86 on Monday. The business has a 50 day moving average price of $3.58 and a two-hundred day moving average price of $3.68. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. Equities research analysts forecast that Tenax Therapeutics will post -6.68 EPS for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.